1. Market Research
  2. > Healthcare Market Trends
  3. > Review of the Healthcare System and Medical Device Market in Belgium – report

This TforG Healthcare Market review report for Belgium includes numerical and written analysis on the socioeconomic and macroeconomic context and outlook, the healthcare system, and the latest healthcare reforms. Moreover, an extensive chapter is dedicated to the markets for capital equipment, medical devices, disposables and pharmaceuticals.

The report helps businesses gain a unique insight into the socio-economic dynamics, and helps analyze how they affect healthcare systems and their evolution. It can serve as a valuable tool with actionable guidance for sales, marketing, R&D and business managers with industry related interests.

Four chapters cover the numerical and written analysis for the following topics: Economic Outlook (38 Key industry indicators), The Healthcare System (HC system structures), Reforms (restructuring, re-engineering or austerity efforts) and the Healthcare Market (Capital Equipment, Medical Devices, Disposables and Pharmaceuticals).

Economic Outlook:
-The GDP in 2014 was 402 bln Euro, equivalent to 36,086 Euro per capita, with an annual growth rate of 1.1 percent.
-Belgium is considered to be one of the most highly industrialized countries in the EU. It relies on importing raw materials in large volumes, processing them, and exporting them again successively.
-It has an advantageous logistical position located near the heart of Europe, well connected by sea and land. This innate benefit facilitates economic activity and growth.
-Exports are equal to 86 percent of its GDP, 75 percent of its trading partners are within the EU, and from amongst all the EU countries it ranks sixth as the largest importer and exporter of goods and services.
-Government spending was around 24.148 m Euro in the first quarter of 2015.
-Belgium ended 2014 with a budget deficit of 3.19 percent of GDP.

The Healthcare System:
-Funding for the healthcare system is pooled at a regional and federal level, and redistributed through the social security department.
-Healthcare spending in 2014 was equal to approximately 10.8 percent of the national GDP.
-76.1 percent of healthcare spending (not accounting for investments) was funded by public sources, higher than the OECD average of 72 percent. The remaining 23.9 percent was paid for by private sources including patient contributions.
-Approximately 2.8 percent of the total expenditure of healthcare in Belgium is spent on medical technology.
-Products and procedures can apply for inclusion into the nationally insured product catalogue issued by the national insurance provider RIZIV.
-Healthcare insurance coverage in Belgium is universal and mandatory. There are five major and competing public health insurance entities.
-Highly specialized care is mainly offered at university hospitals.

-Challenges that the Belgian healthcare faces include: that the reimbursement model does not reflect quality, the discrepancy in hospital doctor’s incomes, the greying of the population, the increasing underfinancing of hospitals leading to overproduction, and negative accounting balances in hospitals.
-Reforms include the 6th State Reform (2014), where a transference of tasks and financing allocates greater decision-making power to regional authorities.
-Public tenders (2013)
-Third-Payer-Regulation (2014) and Social Third-Payer-Regulation (2015)
-The Medical Device Plan (2014)

The Markets:
-The Belgian healthcare market is worth 4.5 bln Euro and forecasted to grow around 3.5 percent by 2018.
-The healthcare sector’s added value to the Belgian economy is equal to nearly eight percent of GDP and it employs twelve percent of the working population.
-There are over 200 active life sciences companies in Belgium, ranging from individual and/or interconnected small to medium-sized enterprises to large corporations.
-Belgium represents approximately 3.3 percent of the European medical technology market.
-The pharmaceutical market is worth approximately 4.49 bln Euro. The greatest markets within the pharmaceutical sector are reimbursed ambulatory drugs and drugs introduced into the market more than five years ago.
-An environment of cooperation and funding mechanisms have fostered collaborations for the pharma and life science R&D market in Belgium.
-Yearly over 2.35 bln Euro is invested into pharma R&D. Belgium ranks number two in the world as performing the highest number of clinical trials per capita.

Reasons to buy:
– Accurate analysis of trends, opportunities and challenges of the economy and healthcare industry
– Relevant healthcare reforms
– Written and numerical analysis on important healthcare indicators (eg.: acute care data, critical care data, anesthesia data, emergency data, healthcare professionals)
– Regularly updates, at least once year
– Every update published by TforG within 6 months after your purchase will be made available to you
– Global coverage, available for + 40 countries
– Unique insight into the socio-economic dynamics, and analysis of their effect on healthcare systems

Table Of Contents

Review of the Healthcare System and Medical Device Market in Belgium - report
Executive Summary
Chapter 1 - Socioeconomic Outlook
1.1 Socioeconomic Context
1.2 Macroeconomics
Table 1.1 - Macroeconomics (2012 - 2017)
1.4 Overview and Outlook
Chapter 2- The Belgian Healthcare System
2.1 Introduction
2.2 Healthcare Status
2.3 Healthcare Expenditures
Table 2.1 - Healthcare (2012 -2017)
2.4 The Organization
2.5 National Level
Diagram 2.1 - Healthcare Organization (2015)
2.6 Regional Level
2.7 Local Level
2.8 Primary Care
2.9 Secondary Care
Diagram 2.1 - Healthcare Organization
2.10 Tertiary Care
2.11 Healthcare Insurance
2.12 Healthcare Financing
2.13 Financial Flows
Diagram 2.2 - Financial Flows (2015)
2.14 Private versus Public
Chapter 3 - Healthcare Reforms
3.1 Current Challenges
3.2 Recent Reforms
3.3 Hospital Operations and Priorities
Chapter 4 - The Markets
4.1 Market Profile
4.2 Purchase Processes and Decision-Making
4.3 Pharmaceuticals
4.4 Capital Equipment and Medical Devices
4.5 Medical Disposables
4.6 Opportunities and Market Drivers
Chapter 5 - Country Overview
5.1 Demographics, Macroeconomics and Healthcare
Chapter 6 - National Care Provision Data
6.1 Acute Care Data (2014)
6.2 Critical Care (2014)
6.3 Anesthesia (2014)
6.4 Emergency (2014)
6.5 Hospital Services Data (2014)
6.6 Healthcare Professionals (2014)
Chapter 7 - The TforG Methodology
7.1 Primary Research
7.2 Secondary Research
7.3 Our Experience

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Psoriatic Arthritis Pricing, Reimbursement, and Access

Psoriatic Arthritis Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • June 2016
  • by Datamonitor Healthcare

An absence of head-to-head trials, along with biosimilar launches, provide payers with leverage to demand favorable pricing for branded products in exchange for formulary access. This report addresses ...

Adhesion Barrier Market by Product, Product Form, Application - Global Forecast to 2021

Adhesion Barrier Market by Product, Product Form, Application - Global Forecast to 2021

  • $ 5 650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global adhesion barriers market is expected to grow at a CAGR of 8.4% during the forecast period of 2016 to 2021. This market is projected to reach USD 1,216.8 million by 2021 from USD 812.5 million ...

Healthcare Supply Chain Management Market by Component, Purchasing, Hardware, Delivery Mode and End User - Global Forecast to 2021

Healthcare Supply Chain Management Market by Component, Purchasing, Hardware, Delivery Mode and End User - Global Forecast to 2021

  • $ 5 650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The healthcare supply chain management market is projected to reach USD 2.22 billion by 2021 from USD 1.45 billion in 2016, growing at a CAGR of 8.9% during the forecast period. Factors such as the Unique ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.